BetterLife Pharma (BETRF) EBITDA (2015 - 2019)

BetterLife Pharma has reported EBITDA for 5 years, with the latest figure at -$1.2 million in Q2 2019.

• On a quarterly basis, EBITDA rose 13.72% year-over-year to -$1.2 million in Q2 2019; TTM through Apr 2019 was -$5.3 million, a 128.78% decrease from a year earlier, with the FY2026 full-year figure at -$1.2 million, up 68.19% from the prior year.
• EBITDA was -$1.2 million for Q2 2019 at BetterLife Pharma, up from -$1.4 million in the prior quarter.
• The five-year high for EBITDA was -$7756.1 in Q4 2015, with the low at -$6.8 million in Q1 2016.
• Average EBITDA over 5 years is -$1.5 million, with a median of -$1.2 million recorded in 2016.
• The sharpest annual moves came in 2016 and 2017: EBITDA sank 8800.1% in 2016, then soared 91.43% in 2017.
• Over 5 years, EBITDA stood at -$7756.1 in 2015, then tumbled by 8800.1% to -$690304.0 in 2016, then jumped by 63.96% to -$248755.0 in 2017, then tumbled by 467.55% to -$1.4 million in 2018, then advanced by 11.6% to -$1.2 million in 2019.
• The last three EBITDA figures came in at -$1.2 million (Q2 2019), -$1.4 million (Q4 2018), and -$1.2 million (Q3 2018), per Business Quant data.